Last reviewed · How we verify
UC-MSC sEV
At a glance
| Generic name | UC-MSC sEV |
|---|---|
| Also known as | Cellistem®sEV-OA |
| Sponsor | Universidad de los Andes, Chile |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Intra-articular Injection of UC-MSC Exosome in Knee Osteoarthritis (EARLY_PHASE1)
- Potential Use of Autologous and Allogeneic Mesenchymal Stem Cells in Patients With Multiple System Atrophy (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- UC-MSC sEV CI brief — competitive landscape report
- UC-MSC sEV updates RSS · CI watch RSS
- Universidad de los Andes, Chile portfolio CI